Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood 2021 11 25;138(21):2138-2142

Date

09/10/2021

Pubmed ID

34499715

Pubmed Central ID

PMC8617436

DOI

10.1182/blood.2021012392

Scopus ID

2-s2.0-85119700502   1 Citation

Author List

Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM

Authors

Amy Moskop MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Antineoplastic Agents, Immunological
Child
Child, Preschool
Female
Humans
Immunotherapy, Adoptive
Infant
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Receptors, Antigen, T-Cell
Retrospective Studies
Treatment Outcome
Young Adult